WillItSurvive
No grouping · United States

BioVentrix, Inc.

Clinical-stage device maker treating heart failure by reshaping the heart after a heart attack.

Protection under test
Assessed 29 July 2026 · Evidence as of 29 July 2026
Something worth protecting exists and is being tested right now.
On the recordSince 29 July 2026 · Checkable from Q2 2026 · Every call on the record Checkpoint: Nasdaq IPO pricing under ticker BVXX and RELIVE pivotal trial enrollment update
The call

BioVentrix has real clinical and regulatory ground covered in a hard-to-enter niche, but with under $1M in cash and a going-concern warning, the balance sheet decides its fate before Medtronic or anyone else needs to.

BioVentrix develops a medical device to treat a type of heart failure by reshaping the heart muscle. The company has regulatory approvals and test results that are hard for competitors like Medtronic or Abbott to copy quickly, but it only has $924,000 in the bank and owes far more than it has, raising serious questions about whether it can stay in business. The one thing that matters most right now is whether the company can raise enough money through its planned stock offering before cash runs out, and whether its ongoing heart patient trials show the device is safe and works well.

Why
01
AI pressure: None apparent. AI diagnostics and imaging tools don't compete with implantable cardiac devices; the near-term threat here is cash, not code. Could AI do the core job? Unlikely.
02
Bigger players: Medtronic, Abbott, Edwards Lifesciences. These structural heart players have capital and sales forces to enter ischemic HFrEF if BioVentrix proves the category, but none has a matching product live today. Could a giant copy it? No, they are blocked.
03
What protects it. FDA Breakthrough Device status, a 2016 CE mark, and years of clinical data on Revivent TC that a new entrant can't shortcut.
What would change this call
BioVentrix IPO priced below $25M or withdrawn from Nasdaq listing (ticker BVXX). Signals liquidity crisis and inability to fund RELIVE trial through PMA.
Going-concern language removed or retained in next SEC filing after March 2026. Shows whether the company has secured enough capital to resolve solvency doubt.
RELIVE pivotal trial enrollment reaching 126 patients or stalling at current site count. Indicates whether the clinical path to FDA approval is on track or losing momentum.
Key numbers
  • Cash on hand: $924,026 (2026-03-31)
  • Working-capital deficit: $14.6M (2026-03-31)
  • R&D expense up 451% YoY in Q1 (2026-07-09)
Named risks
  • Going-concern doubt with only $924,026 cash against $14.6M working-capital deficit as of March 2026. Severity: high
  • IPO could be withdrawn, downsized, or fail to price given disclosed financial distress. Severity: high
  • PMA approval not targeted until mid-2028, leaving multi-year gap before any US commercial revenue. Severity: medium
  • Recent CEO departure and new Co-CEO/CFO appointments introduce execution risk during IPO. Severity: medium
  • Single bookrunner (Benchmark) and small $17M target raise limit capital cushion if trial costs rise. Severity: medium
Rivals, as read in July 2026
RivalDirectionEvidence
MedtroniccontestingLarge-cap structural heart incumbent could acquire BioVentrix, no direct product overlap as of 2026-07
AbbottcontestingAdjacent structural heart giant with resources BioVentrix lacks amid its 2026 cash crisis
Acoraigaining onSwedish ML-based acoustic heart-failure monitoring device offers alternative non-implant approach
Corvia MedicalcontestingIASD interatrial shunt device is a peer heart-failure device technology per literature
Questions people ask
Is BioVentrix profitable in 2026?
No. BioVentrix is pre-revenue in the U.S. with TTM revenue of $0, a Q1 2026 net loss of $3.3 million, and cash of just $924,026 against a $14.6 million working-capital deficit as of March 31, 2026, per its own S-1 disclosures.
Is BioVentrix's IPO actually happening?
BioVentrix filed its S-1 on February 12, 2026 to list on Nasdaq as BVXX, targeting about $17 million with Benchmark as sole bookrunner. As of July 23, 2026 it still had not appeared on priced or withdrawn IPO lists.
Could AI replace BioVentrix's product?
No. BioVentrix's Revivent System is a physical implant placed via mini-thoracotomy surgery, which is inherently AI-resistant at the point of care. AI could only assist adjacent tasks like patient triage or scar imaging, not the surgical placement itself.
Who is BioVentrix's biggest competitor?
Large structural-heart incumbents Medtronic and Abbott sit adjacent to BioVentrix's niche and could acquire it, but neither directly competes since BioVentrix's Revivent device is not commercially sold at scale anywhere as of July 2026.
When will BioVentrix get FDA approval for Revivent?
BioVentrix's own S-1 targets a PMA approval by mid-2028, following its RELIVE pivotal trial which began enrolling patients in September 2025 under an FDA Breakthrough Device Designation granted in November 2024.
What happened to BioVentrix's CEO?
CEO Jim Dillon departed BioVentrix to lead BiVACOR, with Steven Chartier named President and Co-CEO as of July 6, 2026, a leadership transition occurring during the company's pending Nasdaq IPO process.
Timeline
  • 2026-07-06CEO Jim Dillon departs for BiVACOR; Steven Chartier named President and Co-CEO
  • 2026-05-11Carl Byrnes named CFO during IPO process
  • 2026-03German reimbursement designation announced
  • 2026-02-12S-1 filed publicly for Nasdaq IPO under ticker BVXX, targeting $17M
  • 2025-09RELIVE pivotal trial begins enrolling patients
  • 2025-08-05Confidentially filed for IPO
  • 2024-11FDA grants Investigational Device Exemption under Breakthrough Device Designation
  • 2023-04-13Series A financing of $48.5M closes, led by Andera Partners
  • 2016Revivent System obtains CE mark in Europe
  • 2003Company founded as CHF Technologies
Revision history
29 July 2026
First assessed. Protection under test. The text above is fixed as of this date and is not edited afterwards.
In the same band
Ford MotorWhirlpoolSolventum
More companies protection under test →
Sources